Literature DB >> 12075368

Can post-eradication laboratory containment of wild polioviruses be achieved?

Walter R Dowdle1, Howard E Gary, Raymond Sanders, Anton M van Loon.   

Abstract

The purpose of containment is to prevent reintroduction of wild polioviruses from laboratories into polio-free communities. In order to achieve global commitment to laboratory containment the rationale should be clear and compelling; the biosafety levels should be justified by the risks; and the objectives should be realistic. Absolute containment can never be assured. Questions of intentional or unintentional non-compliance can never be wholly eliminated. Effective laboratory containment is, however, a realistic goal. Prevention of virus transmission through contaminated laboratory materials is addressed by WHO standards for biosafety. The principal challenge is to prevent transmission through unrecognized infectious laboratory workers. Such transmission is possible only if the following conditions occur: infectious and potentially infectious materials carrying wild poliovirus are present in the laboratory concerned; a laboratory operation exposes a worker to poliovirus; a worker is susceptible to an infection that results in the shedding of poliovirus; and the community is susceptible to poliovirus infections. At present it is difficult to envisage the elimination of any of these conditions. However, the risks of the first three can be greatly reduced so as to create a formidable barrier against poliovirus transmission to the community. Final biosafety recommendations must await post-eradication immunization policies adopted by the international community.

Entities:  

Mesh:

Year:  2002        PMID: 12075368      PMCID: PMC2567771     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  Poliovirus containment risks and their management.

Authors:  Radboud J Duintjer Tebbens; Dominika A Kalkowsa; Kimberly M Thompson
Journal:  Future Virol       Date:  2018-08-10       Impact factor: 1.831

Review 2.  The final stages of the global eradication of poliomyelitis.

Authors:  Nicholas C Grassly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-06-24       Impact factor: 6.237

3.  Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.

Authors:  Maren Eggers; Elena Terletskaia-Ladwig; Holger F Rabenau; Hans W Doerr; Sabine Diedrich; Gisela Enders; Martin Enders
Journal:  BMC Infect Dis       Date:  2010-12-09       Impact factor: 3.090

4.  Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis.

Authors:  Nishant Jaiswal; Shreya Singh; Amit Agarwal; Anil Chauhan; Kiran K Thumburu; Harpreet Kaur; Meenu Singh
Journal:  Cochrane Database Syst Rev       Date:  2019-12-19

5.  Prolonged excretion of type-2 poliovirus from a primary immune deficient patient during the transition to a type-2 poliovirus-free world, Israel, 2016.

Authors:  Merav Weil; Lester M Shulman; Sophia Heiman; Tali Stauber; Jacqueline Alfandari; Leah Weiss; Ilana Silberstein; Viki Indenbaum; Ella Mendelson; Danit Sofer
Journal:  Euro Surveill       Date:  2016-11-24

6.  Towards an effective poliovirus laboratory containment strategy in Nigeria.

Authors:  Johnson Muluh Ticha; Kolawole Olatunji Matthew; Abdullahi Walla Hamisu; Braka Fiona; Pascal Mkanda; Peter Nsubuga; Eberto Tesfaye; Kehinde Craig; Etsano Andrew; Obi Emelife; Faisal Shuaib; Akinkugbe Folasade; Johnson Adeniji; Usman Adamu; Mohammed Dallatu; Geoffrey Oyeyinka; Holly Brown; Nwakasik Nnamah; Joseph Okwori; Chukwuike Chinedu; Ibikunle Anibijuwon; Adewumi Olubusuyi; Donbraye Emmanuel; Murtala Bagana; Marycelin Baba; Gumede Nicksy; Richard Banda; Sisay G Tegegne; Ajiboye Oyetunji; Ousmane Diop; O Tomori; Rui G Vaz
Journal:  BMC Public Health       Date:  2018-12-13       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.